EGFR and neoplasm: First- or second-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) (e.g., erlotinib, gefitinib, and afatinib), administered to patients whose tumors harbor these genotype alterations, led to marked tumor response and improved progression-free survival and quality of life over chemotherapy (3–5).